For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenue | 0 | |||
| Research and development | 987,332,000 | |||
| General and administrative | 195,037,000 | |||
| Total operating expenses | 1,182,369,000 | |||
| Loss from operations | -1,182,369,000 | |||
| Interest income | 90,694,000 | |||
| Interest expense | 24,231,000 | |||
| Change in fair value of warrant liability and contingent earn-out shares | -15,358,000 | |||
| Other expense, net | 37,000 | |||
| Total non-operating income, net | 51,068,000 | |||
| Income (loss) before provision for income taxes | -1,131,301,000 | |||
| Benefit from income taxes | 0 | |||
| Net loss | -1,131,301,000 | |||
| Unrealized gain on investments, net | 1,916,000 | |||
| Comprehensive loss | -1,129,385,000 | |||
| Basic EPS | -5.95 | |||
| Diluted EPS | -5.95 | |||
| Basic Average Shares | 190,129,154 | |||
| Diluted Average Shares | 190,129,154 | |||
Revolution Medicines, Inc. (RVMDW)
Revolution Medicines, Inc. (RVMDW)